Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals

BACKGROUND: Recombinant adenovirus serotype 5 (rAd5)-vectored HIV-1 vaccines have not prevented HIV-1 infection or disease and pre-existing Ad5 neutralizing antibodies may limit the clinical utility of Ad5 vectors globally. Using a rare Ad serotype vector, such as Ad35, may circumvent these issues,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J AIDS Clin Res
Main Authors: Fuchs, Jonathan D, Bart, Pierre-Alexandre, Frahm, Nicole, Morgan, Cecilia, Gilbert, Peter B, Kochar, Nidhi, DeRosa, Stephen C, Tomaras, Georgia D, Wagner, Theresa M, Baden, Lindsey R, Koblin, Beryl A, Rouphael, Nadine G, Kalams, Spyros A, Keefer, Michael C, Goepfert, Paul A, Sobieszczyk, Magdalena E, Mayer, Kenneth H, Swann, Edith, Liao, Hua-Xin, Haynes, Barton F, Graham, Barney S, McElrath, M Juliana
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648371/
https://ncbi.nlm.nih.gov/pubmed/26587311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4172/2155-6113.1000461
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados